All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What does the STIMULUS program tell us about combination therapy with MBG453 in MDS?

Featured
Jun 30, 2020
Share:

During the 25th Congress of the European Hematology Association (EHA), the MDS Hub spoke to Amer Zeidan, Yale School of Medicine, New Haven, US. We asked: What does the STIMULUS program tell us about combination therapy with MBG453 in MDS?

What does the STIMULUS program tell us about combination therapy with MBG453 in MDS?

The STIMULUS program represents a number of clinical trials that are evaluating the anti-TIM-3 checkpoint inhibitor, MBG453, for the treatment of myeloid malignancies. Alternative immune checkpoint inhibitors have demonstrated mixed results, and therefore the TIM-3 pathway is being investigated for therapeutic intervention.

In early phase clinical trials, MBG453 combination regimens exhibited promising clinical activity, prompting the further studies that now comprise the STIMULUS program.

Share: